230 related articles for article (PubMed ID: 28203073)
1. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
2. The Swedish α1-Antitrypsin Screening Study: Health Status and Lung and Liver Function at Age 34.
Tanash HA; Nystedt-Düzakin M; Montero LC; Sveger T; Piitulainen E
Ann Am Thorac Soc; 2015 Jun; 12(6):807-12. PubMed ID: 25803183
[TBL] [Abstract][Full Text] [Related]
3. Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.
Mostafavi B; Diaz S; Piitulainen E; Stoel BC; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3689-3698. PubMed ID: 30510411
[TBL] [Abstract][Full Text] [Related]
4. Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.
Schramm GR; Mostafavi B; Piitulainen E; Wollmer P; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2021; 16():3477-3485. PubMed ID: 34992356
[TBL] [Abstract][Full Text] [Related]
5. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals.
Bernspång E; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2009 Jun; 103(6):861-5. PubMed ID: 19181511
[TBL] [Abstract][Full Text] [Related]
6. PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD.
Green CE; Vayalapra S; Hampson JA; Mukherjee D; Stockley RA; Turner AM
Thorax; 2015 Oct; 70(10):939-45. PubMed ID: 26141072
[TBL] [Abstract][Full Text] [Related]
7. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency.
Bernspång E; Sveger T; Piitulainen E
Respir Med; 2007 Sep; 101(9):1971-6. PubMed ID: 17532199
[TBL] [Abstract][Full Text] [Related]
8. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
9. Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of Age.
Piitulainen E; Montero LC; Nystedt-Düzakin M; Stoel BC; Sveger T; Wollmer P; Tanash HA; Diaz S
COPD; 2015 Apr; 12(2):162-7. PubMed ID: 25280185
[TBL] [Abstract][Full Text] [Related]
10. CT lung densitometry in young adults with alpha-1-antitrypsin deficiency.
Bernspång E; Diaz S; Stoel B; Wollmer P; Sveger T; Piitulainen E
Respir Med; 2011 Jan; 105(1):74-9. PubMed ID: 20674322
[TBL] [Abstract][Full Text] [Related]
11. Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age.
Mostafavi B; Diaz S; Tanash HA; Piitulainen E
Medicine (Baltimore); 2017 Mar; 96(12):e6180. PubMed ID: 28328804
[TBL] [Abstract][Full Text] [Related]
12. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes.
Molloy K; Hersh CP; Morris VB; Carroll TP; O'Connor CA; Lasky-Su JA; Greene CM; O'Neill SJ; Silverman EK; McElvaney NG
Am J Respir Crit Care Med; 2014 Feb; 189(4):419-27. PubMed ID: 24428606
[TBL] [Abstract][Full Text] [Related]
13. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.
Mostafavi B; Piitulainen E; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2019; 14():525-530. PubMed ID: 30880942
[TBL] [Abstract][Full Text] [Related]
14. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.
Franciosi AN; Hobbs BD; McElvaney OJ; Molloy K; Hersh C; Clarke L; Gunaratnam C; Silverman EK; Carroll TP; McElvaney NG
Am J Respir Crit Care Med; 2020 Jul; 202(1):73-82. PubMed ID: 32197047
[No Abstract] [Full Text] [Related]
15. An association between plasma levels of α2-macroglobulin and α1-antitrypsin in PiMM and PiZZ individuals differing in COPD presentation.
Lechowicz U; Martinez-Delgado B; Liu B; Wrenger S; Rozy A; Zdral A; DeLuca DS; Welte T; Janciauskiene S; Chorostowska-Wynimko J
Clin Biochem; 2024 Apr; 126():110736. PubMed ID: 38428450
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen E; Tanash HA
COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
[TBL] [Abstract][Full Text] [Related]
17. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
18. Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?
Carleo A; Chorostowska-Wynimko J; Koeck T; Mischak H; Czajkowska-Malinowska M; Rozy A; Welte T; Janciauskiene S
Int J Chron Obstruct Pulmon Dis; 2017; 12():829-837. PubMed ID: 28331304
[TBL] [Abstract][Full Text] [Related]
19. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.
Tanash HA; Ekström M; Rönmark E; Lindberg A; Piitulainen E
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889108
[TBL] [Abstract][Full Text] [Related]
20. The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency.
Bernspång E; Carlson J; Piitulainen E
Scand J Gastroenterol; 2009; 44(11):1349-55. PubMed ID: 19891586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
